Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/157947 |
Resumo: | OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX. |
id |
USP-19_407db1fa5b4d433af9a4bfa96514ceab |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/157947 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s DiseaseCrohn’s DiseaseInfliximabAntibodyDrug MonitoringOBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-05-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/15794710.6061/clinics/2019/e824Clinics; Vol. 74 (2019); e824Clinics; v. 74 (2019); e824Clinics; Vol. 74 (2019); e8241980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/157947/153226https://www.revistas.usp.br/clinics/article/view/157947/153575Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessGomes, Luis Eduardo MianiSilva, Francesca Aparecida Ramos daPascoal, Lı´via BitencourtRicci, Renato LazarinNogueira, GuilhermeCamargo, Michel GardereAyrizono, Maria de Lourdes SetsukoFagundes, João JoséLeal, Raquel Franco2019-05-24T13:16:00Zoai:revistas.usp.br:article/157947Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-24T13:16Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
title |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
spellingShingle |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease Gomes, Luis Eduardo Miani Crohn’s Disease Infliximab Antibody Drug Monitoring |
title_short |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
title_full |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
title_fullStr |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
title_full_unstemmed |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
title_sort |
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease |
author |
Gomes, Luis Eduardo Miani |
author_facet |
Gomes, Luis Eduardo Miani Silva, Francesca Aparecida Ramos da Pascoal, Lı´via Bitencourt Ricci, Renato Lazarin Nogueira, Guilherme Camargo, Michel Gardere Ayrizono, Maria de Lourdes Setsuko Fagundes, João José Leal, Raquel Franco |
author_role |
author |
author2 |
Silva, Francesca Aparecida Ramos da Pascoal, Lı´via Bitencourt Ricci, Renato Lazarin Nogueira, Guilherme Camargo, Michel Gardere Ayrizono, Maria de Lourdes Setsuko Fagundes, João José Leal, Raquel Franco |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Gomes, Luis Eduardo Miani Silva, Francesca Aparecida Ramos da Pascoal, Lı´via Bitencourt Ricci, Renato Lazarin Nogueira, Guilherme Camargo, Michel Gardere Ayrizono, Maria de Lourdes Setsuko Fagundes, João José Leal, Raquel Franco |
dc.subject.por.fl_str_mv |
Crohn’s Disease Infliximab Antibody Drug Monitoring |
topic |
Crohn’s Disease Infliximab Antibody Drug Monitoring |
description |
OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-13 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/157947 10.6061/clinics/2019/e824 |
url |
https://www.revistas.usp.br/clinics/article/view/157947 |
identifier_str_mv |
10.6061/clinics/2019/e824 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/157947/153226 https://www.revistas.usp.br/clinics/article/view/157947/153575 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 74 (2019); e824 Clinics; v. 74 (2019); e824 Clinics; Vol. 74 (2019); e824 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222764121980928 |